Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.
about
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantationThe perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionDetection and clinical relevance of donor specific HLA antibodies: a matter of debateMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Detection of HLA Antibodies in Organ Transplant Recipients - Triumphs and Challenges of the Solid Phase Bead AssayAntibody Subclass Repertoire and Graft Outcome Following Solid Organ TransplantationLuminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion.Antibody desensitization therapy in highly sensitized lung transplant candidates.An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLACharacteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipientsImplications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipientsChallenges with sensitized recipients in pediatric heart transplantation.From Humoral Theory to Performant Risk Stratification in Kidney Transplantation.Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes.Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver TransplantationMultiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Emerging uses for pediatric hematopoietic stem cells.Cardiac antibody-mediated rejection.Luminex and antibody detection in kidney transplantation.Prediction of organ transplant rejection by HLA-specific and non-HLA antibodies--brief literature review.The future of heart transplantation.Liver transplantation with a strongly positive crossmatch: case study and literature review.Immunosuppression following heart transplantation: prospects and challenges.Humoral immunity in renal transplantation: epitopes, Cw and DP, and complement-activating capability--an update.Transplant immuno-diagnostics: crossmatch and antigen detection.Current State of Pediatric Lung Transplantation.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.Application, technical issues, and interpretation of C1q for graft outcome.Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance.Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.Changes in the methodology of pre-heart transplant human leukocyte antibody assessment: an analysis of the United Network for Organ Sharing database.Role and Value of Luminex(®)-Detected HLA Antibodies before and after Kidney Transplantation.Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.Meeting report: 2nd international conference: antibody incompatible transplantation and transplant infectious disease.The interplay of donor-specific antibodies, allograft C4d deposition, and antibody-mediated rejection.Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients.Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
P2860
Q26780271-AC7B68C1-9064-49A3-A12F-08A3E2DB71F9Q26862195-D692265B-6E31-46D8-A7E6-049D3690A487Q26998713-17AE7E4B-35CD-4182-A3AA-B2BEF6F35795Q27314948-40EE6ACF-CFFF-4707-9BB3-F31787389BE1Q28075921-09960D7C-4C0F-477C-9496-18E65BE15C11Q28076193-BE1AACB3-4B68-4F93-A104-7B4EB3180B86Q33409582-02E2DA20-4C1D-4375-BF2E-9685AE45E7A4Q33414196-12B84609-7B5A-41C0-BAE4-8311F38D3027Q36302476-DC42B722-66D1-4FE6-B075-6BC096917B9FQ36509321-3FF2FB64-BCC7-42FE-91A1-12792C97B7C1Q36772957-C1526C3D-1F09-4AB3-91F5-306143DE157FQ36999202-5025D38E-0754-4775-A58E-8C8262FE570DQ37013494-E107F525-1B9B-4A0A-BC57-36A53769D2D0Q37446864-1BA2710E-1CD6-4ADC-9CED-C651B237605EQ37590820-468B4065-53A2-41A2-94FD-F0FD65E0AEBFQ37609092-2228F7E4-20E5-4EF2-9584-B63CFE077D49Q37616457-F48E091C-E31A-498A-AE9B-CAC70040F29FQ37677278-968305D5-3515-4F07-A2D2-80B7D39310D2Q37978779-84234E4A-8FE3-46ED-8BA3-41FB178F9FBAQ38002449-0E5939F9-0471-478C-9FCB-9FB7F658756AQ38007085-11E8F2CA-1B23-4D00-A62A-DA07BDE842EBQ38019584-E473AED4-4829-421F-8E03-C6A665ABD690Q38035388-A26E752B-0E32-4B0B-A390-706FBDF57266Q38116841-49A807C8-4A8C-479D-A2F8-312FB4E24A33Q38184649-D3F31CED-09A4-47FC-AE08-4E536ADF01AFQ38341785-AB6FA537-9B8D-4E85-A226-0F1D6B795FABQ38542338-CA6BB4D5-982D-400B-A449-BD5FEEE66265Q38978016-FB07747B-E9FB-47B6-B4E1-F88D681F20C6Q39366396-38493AEE-A847-4E54-BF3C-CED3057D4229Q39402829-7514272D-3A91-4EA9-B626-4DC9E9CC96D3Q39445381-6AAD30E5-9187-41D1-B209-AF118B57E9BFQ40310759-1498B3C1-A769-4BAA-891A-976AB7E935CAQ40634986-E7022C00-EFFB-463D-A5C3-5F0F31EA729CQ40739859-012DE37B-9C15-41AE-848B-5D0D92F07DE8Q41826794-5C920A2D-DA02-4B36-B30B-494CFA83BBFDQ41849097-5C67613E-6DE7-47A8-8C54-D6984547BD3DQ43461676-06575B27-434F-4355-B88C-7C3A898CC893Q44940147-A4B8D308-2B9B-493E-9490-FDE06FA7C2D9Q45930637-B5BB1A0D-FEE8-4D0F-8AF6-5C67D0B7C94CQ45972310-66FEF8CE-8FB3-400E-B822-8C7A563EA26C
P2860
Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Clinical usefulness of a novel ...... ric heart transplant patients.
@en
Clinical usefulness of a novel ...... ric heart transplant patients.
@nl
type
label
Clinical usefulness of a novel ...... ric heart transplant patients.
@en
Clinical usefulness of a novel ...... ric heart transplant patients.
@nl
prefLabel
Clinical usefulness of a novel ...... ric heart transplant patients.
@en
Clinical usefulness of a novel ...... ric heart transplant patients.
@nl
P2093
P1476
Clinical usefulness of a novel ...... tric heart transplant patients
@en
P2093
Clifford Chin
Daniel Bernstein
Dolly Tyan
Flavia Sequeria
Gerald Berry
Olaf Reinhartz
Stephanie Siehr
P304
P356
10.1016/J.HEALUN.2010.08.020
P577
2010-10-15T00:00:00Z